There is evidence that modulators improve pancreatic exocrine and endocrine function, CF liver disease, bone disease [141], and have effects on haemopoietic cells [142,144], indicating that they have a broad scope of action across a range of cell types, supporting their potential for direct effects on defective CFTR expressed in immune cells. The gene discussed is CFTR; the disease is liver disorder.